Dynavax breakout ahead of Heplisav approval

做多

Dynavax Technologies Corporation (NASDAQ:DVAX)

NASDAQ:DVAX Dynavax Technologies Corporation

Trend Analysis Beyond Technical Analysis biotech

trendanalysis beyondta biotech

Start of final bull run ahead of 9th November FDA announcement of Heplisav approval
$25-$30 price projection

免责声明

这些信息和出版物并不意味着也不构成TradingView提供或认可的金融、投资、交易或其它类型的建议或背书。请在使用条款阅读更多信息。